Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Sunday, June 1, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward oncologists, medical oncologists, and other HCPs involved in the treatment and management of EGFR-NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss guideline-recommended strategies for biomarker testing to detect EGFR mutations in patients with metastatic NSCLC
- Outline current and emerging treatment strategies for EGFR-mutated metastatic NSCLC
- Integrate recent data and guideline-based recommendations when developing personalized care plans for patients with metastatic, EGFR-mutated NSCLC
- Identify appropriate strategies for the prevention and management of toxicities associated with EGFR-targeting therapies for metastatic NSCLC
Balazs Halmos, MD, MS
Professor of Clinical Medicine
Director, Thoracic/Head and Neck Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, NY
Disclosures: Consultant: Apollomics, AstraZeneca, BMS, Boehringer Ingelheim, Daiichi, Eli-Lilly, Genentech, GSK, Johnson & Johnson, Merck, Pfizer, Takeda; DSMC: Apollomics, BMS, City of Hope, Nuvalent, TPT, eFECTOR; Research grant (paid to institution): AbbVie, Advaxis, Amgen, Arrivent, AstraZeneca, Beigene, Black Diamond Therapeutics, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Forward Pharma, GSK, Janssen, Merck, Numab, Pfizer
Enriqueta Felip, MD, PhD
Professor of Medicine, Universitat Autรฒnoma de Barcelona (UAB)
Section in Chief, Medical Oncology Department
Director Thoracic Oncology Unit
Vall dโHebron University Hospital
Vall dโHebron Institute of Oncology (VHIO)
Barcelona, Spain
Disclosures: Consulting Fee: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daichii-Sankyo, F. Hoffmann-La Roche, Gilead, Glaxo Smith Kline, Janssen, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Pierre Fabre, Pfizer, Regeneron, Sanofi, Turning Point; Independent Member of the Board: Grifols; Speakerโ Bureau: Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Gilead, Janssen, Johnson & Johnson, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, Novartis, Peervoice, Pfizer, Regeneron, Takeda; Support for attending meetings/travel: AstraZeneca, Johnson & Johnson, Roche
Julia Rotow, MD
Assistant Professor
Harvard Medical School
Clinical Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squib, Daiichi-Sankyo, Genentech, Gilead, Jazz, Johnson & Johnson, Merus, Novocure, Pfizer; Contracted for research (to institution): AbbVie, Altor Bioscience, AstraZeneca, Bicycle Therapeutics, BioAtla, Black Diamond Therapeutics, Blueprint Medicines, Duality, Enliven Therapeutics, EpimAb, Immunity Bio, LOXO Oncology, ORIC Pharmaceuticals, RedCloud Bio, Regeneron, Summit, Synthekine; Honoraria: AstraZeneca, Daiichi-Sankyo, Pfizer
Faculty, Staff, and Plannersโ Disclosures
The staff of Physiciansโ Education Resourceยฎ, LLC (PERยฎ) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patientโs medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.